Human immunodeficiency virus type 1 (HIV-1
Human immunodeficiency virus type 1 (HIV-1) infection leads to depletion of T helper cells and immune dysfunction, resulting in immunodeficiency and thus vulnerability to opportunistic infections. Formerly a death sentence, infection by HIV-1 can be managed effectively by treatment with multiple drugs targeting the viral enzymes, reverse transcriptase and protease. Such combination therapy results in a dramatic reduction in the level of circulating virus and minimizes the emergence of drug-resistant viral mutants. However, even the most effective current therapy fails to eliminate the virus, and incomplete patient adherence to therapy promotes the emergence of drug-resistant mutants. These issues have promoted the development of antiviral compounds targeting novel steps in infection, including fusion and integration. Historically, the virus-specific enzymes have been preferred targets for therapy due to the facility of biochemical assays for screening. Nonetheless, any viral function that is essential for replication may be considered as a potential target for antiviral drug development.
Retroviruses such as HIV-1 contain an internal viral RNAprotein complex surrounded by a protein shell, termed the capsid, which consists of a polymer of the viral protein CA arranged in a hexameric lattice (12) . These components collectively comprise the viral core. Upon virus fusion with a susceptible host cell, the core is released into the target cell. Although the ensuing stages are poorly understood at a molecular level, the capsid is thought to undergo a controlled disassembly reaction in order for reverse transcription of the viral genome to occur (10) . This process, termed uncoating, appears to be perturbed by restrictive host factors that target CA, including simian TRIM5␣ proteins, and by mutations in CA that alter the structure and/or stability of the capsid (9, 10, 23, 30, 33) . Premature uncoating results in attenuated reverse transcription in target cells (21, 27) . Another host protein, cyclophilin A (CypA), interacts with HIV-1 CA in target cells and facilitates infection by an unknown mechanism (19, 31) . CypA also potentiates restriction of HIV-1 by simian TRIM5␣ proteins, which target the viral capsid upon penetration into target cells and lead to impaired reverse transcription. Although the molecular mechanism of TRIM5␣-dependent restriction has not been fully defined, one attractive model involves acceleration of virus uncoating in target cells (26, 27) .
Here we describe the mechanism of action of a newly identified HIV-1 inhibitor that targets the CA protein. We show that the compound destabilizes the viral capsid. The study identifies a novel antiviral mechanism, highlights CA as a viable target for antiviral therapy, and introduces a novel pharmacologic probe for analyzing the early postentry events in HIV-1 infection.
MATERIALS AND METHODS
Viruses and cell lines. The full-length HIV-1 molecular clone R9 (11) , and its corresponding CA mutant derivatives (10) , were used in these experiments. The 5Mut derivative contains five substitutions in the CA coding sequence, resulting in the following codon changes: Q67H, K70R, H87P, T107N, and L111I. For experiments involving SIV, a full-length molecular clone of SIVmac239 containing a frameshift in the Env coding sequence was used, and particles were pseudotyped with vesicular stomatitis virus glycoprotein (VSV-G) by cotransfec-tion of 293T cells with the proviral plasmid and pHCMV-G (37). LacZ-transducing MLV reporter particles were produced by transfection of 293T cells with the expression vector pCIG3B (4), expressing B-tropic MLV Gag-Pol, together with pCL-lacZ (20) and pHCMV-G. To generate stable CypA-depleted cells, TZM-bl reporter cells (34) were transduced with pGIPZ-based lentiviral vectors encoding short hairpin RNAs (shRNAs) specific for human TRIM5␣ and CypA. Stable transduced cell populations were selected with puromycin and subsequently used in assays of HIV-1 infection. Functional depletion of CypA was confirmed by titration of the cyclosporine (Cs)-dependent HIV-1 CA mutant A92E, which is not attenuated in CypA-depleted cells (22) .
PCR quantification of reverse transcription. HeLa-P4 cells were inoculated with DNase I-treated stocks of Env-defective HIV-1 (R9.EnvϪ) pseudotyped with VSV-G in the presence or absence of PF74 (10 M) or Efavirenz (5 nM). After 8 h of culture, the cells were harvested and DNA isolated with a DNeasy Blood & Tissue kit (Qiagen). HIV-1 DNA in the samples was quantified by real-time PCR using primers specific for products formed after the second strand transfer-5Ј-AGCAGCTGCTTTTTGCCTGTACT-3Ј and 5Ј-CCTGC GTCGAGAGATCTCCTCTGG-3Ј-with SYBR green detection in a Stratagene MX3000p instrument. Antiviral assays. Stock solutions of PF74 were prepared at 10 mM in dimethyl sulfoxide (DMSO). For antiviral assays up to a 10 M final concentration, the compound was diluted to 1 mM in DMSO and added directly to prediluted viruses to the desired final concentrations. Infection assays were performed in HeLa-P4 (HeLa-CD4/LTR-lacZ) (5) or TZM-bl (34) reporter cells. Infections were quantified following visualization of infected cells by X-Gal (5-bromo-4-chloro-3-indolyl-␤-D-galactopyranoside) staining, as previously reported (36) . Control assays with DMSO demonstrated no effect of the solvent at the final concentrations present in the PF74-containing assays.
Assays of HIV-1 capsid stability. HIV-1 cores were purified as previously described (15) . In experiments involving treatment with PF74, concentrated virus suspensions were incubated with or without the compound at the final concentrations for 1 h at room temperature and subsequently cooled to 4°C prior to the ultracentrifugation through a layer containing 1% Triton X-100. Fractions were harvested from the top of the gradient, and the CA protein in each fraction was quantified by p24 enzyme-linked immunosorbent assay (ELISA). The recovery of core-associated CA protein was determined as a percentage of the total CA protein in each gradient. Uncoating of purified cores was assayed as previously described (1) .
Assay of HIV-1 uncoating in target cells. The effect of PF74 on HIV-1 capsid stability in target cells was analyzed by density gradient separation of cell lysates, as previously described (27) . Briefly, cultures of 5 ϫ 10 6 CrFK cells in 100-mm dishes were inoculated with 10 ml of VSV-G-pseudotyped wild-type or 5Mut HIV-1 particles (corresponding to about 5 ϫ 10 6 cpm of reverse transcriptase activity). The virus was preincubated with PF74 (10 M) or carrier DMSO (0.1%) for 30 min at room temperature and then added to cultures (prewashed with phosphate-buffered saline [PBS]) for 30 min at 4°C, after which the cultures were incubated at 37°C for 4 h. Cultures were treated with Pronase E (Sigma) in PBS to detach cells from the dish. After lysis with hypotonic buffer, the cell lysate was loaded onto a 10-ml 30 to 50% sucrose gradient with a 1-ml 50% sucrose cushion at the bottom. Tubes were centrifuged in a Beckman SW32.1 Ti rotor at 32,000 rpm for 16 h at 4°C. After centrifugation, the pellet was dissolved in 0.5% Triton X-100 in PBS. Both pellet and cell lysate were analyzed for CA content by p24 ELISA. The percentage of pelleted CA was calculated as the total amount of CA in the pellet divided by the total quantity of CA in the supernatant and the pellet.
RESULTS
A series of novel HIV-1 inhibitors was identified in a highthroughput antiviral assay encompassing the full HIV-1 replication cycle (3). PF-3450074 (henceforth referred to as PF74) (Fig. 1A) and a cluster of structurally related compounds inhibited HIV-1 replication at submicromolar concentrations by targeting a postentry stage prior to reverse transcription. These compounds exhibited no inhibitory activity toward HIV-1 protease or reverse transcriptase activity in biochemical assays. Furthermore, HIV-1 mutants resistant to reverse transcriptase inhibitors remained sensitive to PF74. PF74 inhibited a wide variety of HIV-1 isolates with similar potency. Selection for drug resistance in culture identified a series of five substitutions in CA that collectively conferred strong resistance upon introduction into an infectious molecular clone (3a). Thus, PF74 inhibits HIV-1 infection at an early step in the virus life cycle, apparently by targeting the viral capsid.
Specificity of retroviral inhibition by PF74. To examine whether inhibition of infection extends to retroviruses besides HIV-1, we assayed infection by HIV-1, simian immunodeficiency virus (SIVmac), and murine leukemia virus (MLV) in the presence of various concentrations of PF74. To eliminate potential differences arising from distinct virus-receptor interactions used by the viruses, each of viruses was pseudotyped by the VSV-G, thus ensuring that all of the viruses use the same endocytic entry pathway and limiting infection to a single cycle. HIV-1 and SIVmac were both markedly inhibited by PF74 concentrations in the low micromolar range (Fig. 1B ). In contrast, PF74 inhibited MLV infection by only 30% at a concentration of 6 M; however, no additional inhibition observed at concentrations as high as 100 M (Fig. 1B ). These results demonstrate the selectivity of PF74 antiviral activity.
PF74 binds specifically to HIV-1 particles. PF74 binds to recombinant CA in vitro with micromolar affinity, occupying a binding pocket in the amino-terminal domain of the two-domain protein (3a) . To determine whether the compound binds to the assembled CA protein within virions, we incubated con- 3 H-labeled PF74 and subsequently purified the particles by density gradient ultracentrifugation to remove the unbound compound. The gradients were fractionated, and virus particles in each fraction were pelleted. The levels of CA protein and radioactivity in each pellet were then quantified.
3 H-PF74 bound to wild-type HIV-1 particles but not to mutant HIV-1 particles containing five amino acid substitutions (Q67H, K70R, H87P, T107N, and L111I) in CA that collectively confer strong resistance to the compound ( Fig. 2A and B) . These data suggest that the antiviral activity of PF74 depends on its ability to associate with CA in the context of the mature HIV-1 particle.
PF74 inhibits HIV-1 reverse transcription in target cells. To more precisely define the stage in infection targeted by PF74, we analyzed the accumulation of reverse transcribed viral DNA in target cells inoculated with HIV-1 in the presence or absence of PF74. Quantitative PCR analysis of HIV-1 cDNA accumulation revealed that addition of the inhibitor resulted in a marked reduction in late products of reverse transcription (Fig. 2C ). These results demonstrate that PF74 inhibits a step in HIV-1 infection prior to completion of reverse transcription.
PF74 destabilizes the HIV-1 capsid. Mutations in CA that either stabilize or destabilize the HIV-1 capsid attenuate infection, indicating that the stability of the capsid must be properly balanced for productive uncoating in target cells (10) . Therefore, we reasoned that binding of PF74 to CA within HIV-1 particles could inhibit infection by either stabilizing or destabilizing the viral capsid lattice. To test this, we purified cores from HIV-1 particles after incubation with the compound. In this assay, positive and negative effects on capsid stability are reflected in an increase or decrease, respectively, in the levels of CA protein cosedimenting with the viral cores (10) . Analysis of the gradient fractions revealed that ca. 20% of the virion-associated CA protein was recovered in the dense fractions of the gradient from the untreated wild-type virions (Fig. 3A) . In contrast, treatment of the virions with PF74 resulted in a marked decrease in the recovery of core-associated CA protein in a dose-dependent manner ( Fig. 3A and B) . The decreased recovery of CA in the cores from the drugtreated wild-type HIV-1 particles indicates that the compound destabilizes the viral capsid. As a control, we performed the analysis of the PF74-resistant HIV-1 mutant. The drug-resistant particles exhibited only a 10% decrease in CA recovery upon treatment with the compound (Fig. 3B) . Thus, the destabilization of the virus capsid by PF74 was specific for wildtype HIV-1.
We next tested the effects of PF74 on the uncoating of purified HIV-1 cores in vitro. Native viral cores were isolated by centrifugation of a suspension of concentrated virions through a detergent layer into a linear sucrose density gradient at 4°C, and the cores were recovered from the gradient fractions. Samples of purified cores were subsequently incubated at 37°C in the presence or absence of PF74, followed by separation of core-associated and soluble CA protein by ultracentrifugation. PF74 potently stimulated the uncoating of wild-type HIV-1 cores in vitro, with an ϳ100% increase observed at 0.25 M (Fig. 3C) . This difference was statistically significant (P ϭ 0.027). In contrast, no significant effect of PF74 was observed on the extent of uncoating of cores purified from the PF74-resistant 5Mut virus. However, much higher concentrations of the compound (10 to 20 M) were capable of stimulating the uncoating of the mutant cores (data not shown).
We also tested the effects of PF74 on the stability of the incoming HIV-1 core in target cells. To do this, we used an approach previously developed for the analysis of retrovirus restriction by TRIM5␣ (27) . Cultures of the highly permissive cell line, CrFK, were inoculated with VSV-G-pseudotyped HIV-1 in the presence or absence of PF74 (10 M). Four hours later, the cells were harvested with Pronase to remove surface-bound particles and subjected to hypotonic lysis and density gradient fractionation by ultracentrifugation. Analysis of the levels of CA in the pellet and supernatant revealed that PF74 markedly reduced the level of pelletable CA in the lysates of cells inoculated with the wild-type virus (Fig. 3D) . In contrast, no significant effect was observed on the PF74-resistant 5Mut virus, which exhibited an overall greater level of pelletable CA protein. Collectively, the results in Fig. 3 demonstrate that PF74 induces the premature dissolution of the HIV-1 capsid in vitro and in target cells. HIV-1 sensitivity to PF74 is modulated by mutations altering the intrinsic stability of the viral capsid. In a previous study, mutations in CA that alter the intrinsic stability of the viral capsid were associated with impaired HIV-1 infectivity (10, 36) . To test whether PF74 antiviral activity is modulated by changes in intrinsic capsid stability, we assayed PF74 inhibition of a panel of HIV-1 CA mutants exhibiting alterations in capsid stability (10) . Although impaired for infection relative to wild-type HIV-1, the mutant viruses retain a sufficient level of infectivity to quantify inhibition by PF74. The hyperstable capsid mutant E45A exhibited reduced sensitivity to inhibition by PF74 relative to wild-type HIV-1 (Fig. 4A) . In contrast, the P38A and Q219A mutants, which contain unstable capsids, were somewhat more sensitive to inhibition by PF74 than the wild type, exhibiting a greater reduction of infection at both low and high inhibitor concentrations. Like the E45A mutant, the Q63A/Q67A mutant was less sensitive to PF74 than wildtype HIV-1. This mutant was previously shown to exhibit unstable cores in vitro (10); however, unlike the other unstable mutants, Q63A/Q67A particles are competent for reverse transcription in target cells and are impaired at nuclear import (8) . Furthermore, Q63A/Q67A preintegration complexes recovered from cells retained elevated levels of CA protein, indicating that this mutant undergoes incomplete or delayed uncoating in target cells (8) . To determine whether altered binding of the compound could explain the changes in drug sensitivity, we assayed the binding of the drug to a subset of these mutants. We observed differences in the extent of com- pound binding to some of the mutants (Fig. 4B) . Specifically, the P38A mutant bound approximately twice as much of the PF74 as wild-type HIV-1 particles, potentially contributing to the increased sensitivity of this mutant to the inhibitor. The inhibitor bound to E45A and Q219A mutant particles to an extent comparable to that of the wild type. In contrast, a small but significant decrease (P ϭ 0.013) in binding to Q63A/Q67A particles was observed relative to the wild type, potentially contributing to the reduced sensitivity of this mutant. The observation that E45A and Q219A mutant particles bind PF74 as efficiently as wild-type HIV-1 indicates that the altered sensitivity of these viruses to the inhibitor is likely owing to their changes in intrinsic capsid stability. The E45A mutant containing hyperstable cores was resistant to the compound, while the Q219A mutant with unstable cores was hypersensitive to the inhibitor. PF74 antiviral activity is promoted by cyclophilin A binding to the viral capsid. The cytoplasmic host protein CypA binds specifically to HIV-1 CA and promotes infection by acting at an early postentry step. Although the precise mechanism by which CypA acts is unknown, one model involves binding to the incoming viral core and protection from an intrinsic antiviral restriction (reviewed in references 19 and 31). To determine whether CypA-CA interactions are involved in the antiviral mechanism of PF74, we tested the effects of Cs on PF74 antiviral efficacy. Cs acts by binding to CypA and inhibiting its association with CA. The MacSynergy II three-dimensional (3D) model of Prichard and Shipman produces predictions of synergy or antagonism by comparing the data generated against a prediction for additivity, which is revealed as a flat surface in a 3D plot. Synergistic interactions cause a positive volume of synergy and antagonistic interactions produce a negative volume of antagonism. Volumes greater than 25 M 2 are considered to indicate moderate synergy or antagonism and volumes Ͼ 100 M 2 indicate strong synergy. Highly synergistic combinations such as when nucleoside and non-nucleoside reverse transcriptase inhibitors are combined produce synergy volumes of 80 to 200 M 2 , whereas highly antagonistic combinations such as d4T and ribavirin are reported to have negative volumes of 300 to 600 M 2 (6, 7, 16) . The interaction between PF74 and Cs produced a clear negative volume (Ϫ129 M 2 ), creating a bowl shape covering the majority of combinations tested (Fig. 5A and B) . These data indicate strong antagonism between the antiviral activity of PF74 and Cs and suggest that the antiviral activity of PF74 is enhanced by CypA.
To confirm that the antagonistic effect of Cs on PF74 antiviral activity is due to Cs inhibition of CypA binding to CA, we tested the antiviral efficacy of PF74 in target cells depleted for CypA expression by RNA interference. Inhibition by PF74 in shRNA-transduced CypA-depleted cells was less effective than in the corresponding control cells transduced with the empty lentiviral vector (Fig. 5C) . Finally, HIV-1 CA mutants (G89V and P90A) with reduced affinity for CypA exhibited reduced sensitivity to PF74 (Fig. 5D) . We conclude that binding of CypA to CA in target cells promotes inhibition of infection by PF74.
DISCUSSION
In this study, we analyzed the mechanism of action of a novel small molecule inhibitor of HIV-1 infection. PF74 inhibits HIV-1 infection by targeting an early postentry step in infection, leading to attenuated reverse transcription. The compound targets the viral capsid, as recently demonstrated by identification of resistance mutations in CA (3a), and by our demonstration that PF74 binds specifically to wild-type HIV-1 but not to the inhibitor-resistant mutant. Our data indicate that PF74 inhibits HIV-1 infection by triggering premature uncoating in target cells. Treatment of HIV-1 particles with PF74 resulted in a decrease in the recovery of CA upon purification of viral cores, and mutations conferring resistance to the compound reduced this effect. PF74 also potently stimulated the uncoating of purified HIV-1 cores in vitro and induced CA solubilization in target cells. Furthermore, sensitiv- to the indicated HIV-1 mutant particles was tested. Samples of concentrated virus particles were incubated with the radiolabeled compound, pelleted, resuspended in PBS, and then repelleted through a 20% sucrose cushion. The pelleted particles were dissolved in sodium dodecyl sulfate-containing sample buffer, and the levels of 3 H and CA protein were quantified by liquid scintillation counting and ELISA, respectively. The ratios of the radioactive signals to the CA protein were calculated and expressed as a percentage of the wild-type value. Shown are the mean values obtained from averaging the data from at least six independent experiments, with error bars representing one standard deviation.
ity to PF74 was modulated by mutations that alter the intrinsic stability of the viral capsid. Specifically, a mutation (Q219A) that reduced capsid stability conferred increased sensitivity to the inhibitor, whereas a mutation (E45A) that stabilizes the core reduced drug efficacy. Neither mutation detectably altered the ability of HIV-1 particles to associate with PF74, suggesting that the resistance of these viruses to the PF74 is independent of effects on compound binding. Intriguingly, infection by the mutant Q63A/Q67A was also markedly resistant to PF74. This mutant, while containing intrinsically unstable capsids, was found to undergo efficient reverse transcription in target cells. Preintegration complexes isolated from cells inoculated with Q63A/Q67A particles exhibited elevated levels of CA relative to wild type, indicative of delayed uncoating in target cells. The resistance of this mutant may therefore also result from an inefficient uncoating in the cell. Recent studies have also demonstrated that the E45A and Q63A/Q67A mutant viruses are impaired for infection of mitotically arrested cells (35) and are less dependent on the nuclear transporter TNPO3 (17) , pointing to a link between HIV-1 uncoating and nuclear entry. While further studies are necessary to determine whether impaired HIV-1 uncoating is sufficient to confer resistance to PF74, the inverse correlation between capsid stability and PF74 sensitivity, coupled with the decreased level of CA associated with cores purified from PF74-treated virions, further support a link between destabilization of the viral capsid by PF74 and its antiviral activity. The effect of PF74 on HIV-1 infection is similar to that observed with HIV-1 mutants containing unstable capsids, the majority of which exhibit inefficient reverse transcription in target cells.
Two other inhibitors targeting the HIV-1 capsid protein have been previously described. The small molecule CAP-1 inhibits HIV-1 capsid assembly in vitro and reduces the infectivity of HIV-1 particles when present at high concentrations during particle formation (14, 29) . CAP-1 does not appear to target uncoating but acts at a late stage of the virus replication cycle. CAI, a dodecapeptide identified as a CA ligand by phage display (25) , inhibits the assembly of mature and immature HIV-1 particles in vitro. The peptide was recently rendered cell-permeable by chemical stapling, and the modified peptide inhibited HIV-1 at both early and late stages of replication (38) . The cell-permeable peptide inhibited HIV-1 particle production and inhibited infection at micromolar concentrations. None of these previous studies reported the identification of HIV-1 resistance mutations, which is critical for unambiguous identification of the drug target.
The dependence of PF74 antiviral potency on CypA binding to CA is noteworthy and has implications for the mechanism of CypA action in HIV-1 infection. Currently, the mechanism by which CypA facilitates HIV-1 infection of human cells is un- (32) , or modulates uncoating (18) . The putative restriction is not mediated by TRIM5␣, since depletion of this protein from human cells did not affect the requirement for CypA-CA association in HIV-1 replication (13, 24) . Remarkably, restriction by the rhesus macaque TRIM5␣ protein is potentiated by host CypA (2, 13, 28) , suggesting that the CypA-CA renders the capsid more vulnerable to the inhibitory effects of simian TRIM5␣. Our finding that CypA also promotes HIV-1 inhibition by PF74 suggests that CypA binding may prime the viral core for uncoating in target cells, thus rendering the virus more susceptible to the destabilizing effects of PF74 as well as restrictive TRIM5␣ proteins. Furthermore, the dependence of both PF74 antiviral activity and TRIM5␣ restriction on CypA-CA interactions suggests a mechanistic similarity between these two HIV-1 inhibitors. Our study revealed two mechanisms for generating HIV-1 resistance to PF74: (i) loss of binding of the compound and (ii) stabilization of the viral capsid. The resistant mutant virus encoding 5 amino acid changes in CA was selected by continuous culture in the presence of the drug. This mutant was markedly reduced in its ability to bind to PF74 (Fig. 2) . In contrast, the core-stabilizing mutants E45A and Q63A/Q67A retained the ability to bind the drug and yet were highly resistant in single-cycle infection assays, suggesting that resistance can also be engendered via capsid stabilization without a loss of drug binding (Fig. 3) . These mutants were previously shown to be impaired for replication in culture and exhibit poor infectivity in single-cycle assays (10) . Thus, resistance to PF74 inhibition by capsid stabilization may initially be accompanied by a strong replicative fitness cost, which could be compensated for by additional mutations. Clinical resistance to the class of inhibitors may therefore be more likely to result from mutations that prevent binding of the inhibitor. Further analysis of the resistance profile to PF74 and related compounds will likely yield additional insights into the relationships between drug binding, capsid destabilization, and antiviral activity.
